The earnings call for Arcutis Biotherapeutics highlighted strong revenue and prescription growth driven by the ZORYVE franchise and recent FDA approval. Despite seasonal factors expected to moderate growth and challenges in Medicare Part D coverage, the positive cash flow and strategic plans suggest a promising outlook.

Company Guidance

In the Arcutis Biotherapeutics 2025 Second Quarter Financial Results Conference Call, the company reported strong financial performance and strategic progress. Net product revenues reached $81.5 million, marking a 28% increase from the previous quarter and a 164% growth compared to the second quarter of 2024. This growth was driven by increased demand for ZORYVE, with prescriptions reaching 16,000 weekly scripts and a total of nearly 200,000 prescriptions in the quarter, reflecting a 13% quarter-over-quarter increase and a 117% year-over-year increase. The company's gross-to-net rates remained stable, supported by strong insurance coverage. Arcutis also highlighted its strategic focus on expanding ZORYVE's indications, with a fifth FDA approval for ZORYVE foam 0.3% for plaque psoriasis of the scalp and body in May. The company is pursuing further label expansions, particularly in pediatric atopic dermatitis, with an upcoming PDUFA date in October for ZORYVE cream 0.05% for children aged 2 to 5. Arcutis is on track for cash flow breakeven in 2026, supported by disciplined capital allocation and a strategic focus on leveraging its development and commercialization capabilities.

Strong Revenue Growth

Arcutis reported net product revenues of $81.5 million in Q2 2025, representing a 28% quarter-on-quarter growth and a 164% increase compared to the same quarter in 2024.

FDA Approval for ZORYVE Foam

Received FDA approval for ZORYVE foam 0.3% for the treatment of plaque psoriasis of the scalp and body, marking the fifth FDA approval for ZORYVE in the last 3 years.

Increased Prescription Volume

ZORYVE prescription volume reached a record high with nearly 200,000 total prescriptions in the quarter, reflecting a year-over-year volume increase of 117% and a quarter-over-quarter increase of 13%.

Positive Cash Flow from Operations

The company reported a positive net cash flow from operating activities of $325,000 in Q2 2025.

Arcutis Biotherapeutics (ARQT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ARQT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.09 / -	-0.33	―	―	―
Aug 06, 2025	2025 (Q2)	-0.14 / -0.13	-0.42	69.05% (+0.29)
May 06, 2025	2025 (Q1)	-0.21 / -0.20	-0.32	37.50% (+0.12)
Feb 25, 2025	2024 (Q4)	-0.26 / -0.09	-0.72	87.50% (+0.63)
Nov 06, 2024	2024 (Q3)	-0.42 / -0.33	-0.73	54.79% (+0.40)
Aug 14, 2024	2024 (Q2)	-0.52 / -0.42	-1.16	63.79% (+0.74)
May 14, 2024	2024 (Q1)	-0.69 / -0.32	-1.31	75.57% (+0.99)
Feb 27, 2024	2023 (Q4)	-0.78 / -0.72	-1.18	38.98% (+0.46)
Nov 03, 2023	2023 (Q3)	-0.91 / -0.73	-1.89	61.38% (+1.16)
Aug 08, 2023	2023 (Q2)	-1.25 / -1.16	-1.31	11.45% (+0.15)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ARQT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$15.36	$14.12	-8.07%
May 06, 2025	$14.32	$13.70	-4.33%
Feb 25, 2025	$12.20	$13.22	+8.36%
Nov 06, 2024	$9.66	$10.40	+7.66%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Arcutis Biotherapeutics Inc (ARQT) report earnings?

Arcutis Biotherapeutics Inc (ARQT) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Arcutis Biotherapeutics Inc (ARQT) earnings time?

Arcutis Biotherapeutics Inc (ARQT) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ARQT EPS forecast?

ARQT EPS forecast for the fiscal quarter 2025 (Q3) is -0.09.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing